Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.
According to Celgene “pricing decisions reflect the benefits that our innovative therapies provide to patients, the healthcare system and society.” Let me translate this statement. Multiple myeloma patients have little choice because conventional oncology prescribes multiple myeloma patients to undergo specific chemotherapies such as Revlimid regardless of the cost, efficacy or side effects.
Please consider evidence-based nutrition, supplementation and lifestyle integrative therapies shown to reduce toxicity while increasing the efficacy of chemotherapy regimens such as Revlimid (bortezomib).
I am both a long-term MM survivor and MM cancer coach. To learn more about managing your MM both conventionally and non-conventionally, please click the button below to sign up for a FREE webinar about Multiple Myeloma treatment options:
Have you been diagnosed with multiple myeloma? To learn more about integrative and complementary MM therapies to enhance the efficacy of revlimid while reducing your risks of side effects, scroll down the page, post a question or comment and I will reply to you ASAP.
“Conclusion: Curcumin exerts a cytotoxic effect additive to that of lenalidomide (revlimid) on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent…”
“So far this year, Celgene has raised the price of Revlimid three times, taking the drug’s list price up 19.8% year to date, according to a note from SunTrust analyst Yatin Suneja. The drugmaker hauled in nearly $7 billion around the world last year with the med that treats multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes…
The company has also raised prices on Pomalyst twice so far in 2017, amounting to a 17.7% jump year to date, Suneja wrote. The multiple myeloma drug brought in $1.3 billion last year…
But the moves come during a tough period for pharma’s reputation, during which lawmakers and the U.S. public have blasted the industry’s pricing and pushed for regulatory reform. Instead, no action has happened on the national level, and some states are taking the issue into their own hands…
In a statement, a Celgene spokesperson said the company’s “pricing decisions reflect the benefits that our innovative therapies provide to patients, the healthcare system and society.” Celgene says the value of its drugs “continue to increase, supported by the growing clinical and real-world outcomes for patients in the approved indications.””